Foundation Medicine, Inc.

Form 4 June 15, 2015

## FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* Yeshwant Krishna

2. Issuer Name and Ticker or Trading Symbol Foundation Medicine, Inc. [FMI] 5. Relationship of Reporting Person(s) to Issuer

(Last) (First) (Middle)

(Zip)

3. Date of Earliest Transaction

(Month/Day/Year) 06/11/2015

(Check all applicable)

X 10% Owner

1600 AMPHITHEATRE

**PARKWAY** 

(City)

4. If Amendment, Date Original

Filed(Month/Day/Year)

\_ Other (specify Officer (give title below)

6. Individual or Joint/Group Filing(Check Applicable Line)

\_X\_\_ Director

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

#### **MOUNTAIN VIEW, CA 94043**

(Street)

(State)

	Table 1- Non-Derivative Securities Acquired, Disposed bi, or Deficiently Own							ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	3. 4. Securities Acquired (D) Transaction Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)			))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	or (D)	Price	(Instr. 3 and 4)	`	
Common Stock	06/11/2015		S	15,734	D	\$ 35.14 (1)	168,126	I	See footnotes (4) (5)
Common Stock	06/12/2015		S	53,645	D	\$ 33.72 (2)	114,481	I	See footnotes (4) (5)
Common Stock	06/15/2015		S	114,481	D	\$ 32.33 (3)	0	I	See footnotes (4) (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: Foundation Medicine, Inc. - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	isable and	7. Titl	le and	8. Price of	9.
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onNumber	Expiration Da	ate	Amou	ınt of	Derivative	D
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	rlying	Security	Se
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Secur	ities	(Instr. 5)	Ве
	Derivative				Securities			(Instr.	3 and 4)		O
	Security				Acquired						Fo
	•				(A) or						Re
					Disposed						Tr
					of (D)						(Iı
					(Instr. 3,						
					4, and 5)						
									Amount		
						Date	Expiration	PD1 - 1	or		
				Exercisable	ble Date Title		Number				
				G 1 17	(A) (B)				of		
				Code V	(A) (D)				Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	Officer	Othe			
Yeshwant Krishna							
1600 AMPHITHEATRE PARKWAY	X	X					
MOUNTAIN VIEW, CA 94043							

# **Signatures**

/s/ Krishna 06/15/2015 Yeshwant \*\*Signature of Date Reporting Person

### **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.90 to \$35.42, inclusive. The Reporting Person undertakes to provide to Foundation Medicine, Inc., any security holder of Foundation **(1)** Medicine, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.00 **(2)** to \$35.26, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$32.00 to \$32.71, inclusive.

**(4)** 

Reporting Owners 2

). Ni Deriv Secu 3ene

Own Follo Repo Γrans Insti

#### Edgar Filing: Foundation Medicine, Inc. - Form 4

These shares were directly held by Google Ventures 2011, L.P. The general partner of Google Ventures 2011, L.P. is Google Ventures 2011 GP, L.L.C. The Reporting Person is a partner at an affiliate of Google Ventures 2011 GP, L.L.C. and disclaims beneficial ownership of all shares except to the extent of his pecuniary interest, if any, therein.

Solely as a result of the Investor Rights Agreement filed as Exhibit 4.1 of the Form 8-K filed by Issuer with the Securities and Exchange Commission on January 12, 2015 and the Reporting Person's position as a partner at an affiliate of Google Ventures 2011 GP, L.L.C., the Reporting Person may have been deemed to have beneficial ownership of the (a) 20,604,288 shares directly held by Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd ("Roche" and together with Roche Holdings, Inc. and Roche Finance Ltd, the "Roche Entities"), (b) 414,823 shares directly held by Roche Finance Ltd, a wholly owned subsidiary of Roche and (c) shares previously held by Third Rock Ventures, L.P. ("TRV"). Google Ventures 2011, L.P. no longer holds shares of the Issuer and, accordingly, the Reporting Person may not be deemed to beneficially own shares directly held by the Roche Entities and TRV. The Reporting Person disclaims beneficial ownership of any shares of Issuer held by any of the Roche Entities and TRV.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.